<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03941756</url>
  </required_header>
  <id_info>
    <org_study_id>2018-0127</org_study_id>
    <secondary_id>NCI-2019-02320</secondary_id>
    <secondary_id>2018-0127</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <nct_id>NCT03941756</nct_id>
  </id_info>
  <brief_title>Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer</brief_title>
  <official_title>Prophylactic Lymphovenous Bypass Procedure Following Axillary Lymphadenectomy in Patients With Inflammatory Breast Cancer: A Prospective, Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot trial studies whether a procedure called lymphovenous bypass would prevent
      lymphedema (arm swelling) in patients with inflammatory breast cancer or non-inflammatory
      breast cancer that has spread to nearby tissues or lymph nodes. The lymphovenous bypass
      procedure creates a path for lymphatic fluid to flow away from the arms. It is usually done
      after a diagnosis of lymphedema. In this study, giving lymphovenous bypass before underarm
      lymph node surgery may help prevent lymphedema from forming.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To evaluate the protective benefit to performing lymphovenous bypass (LVB) surgery at the
      time of axillary lymph node dissection (ALND) for patients that are high risk for developing
      breast-cancer related lymphedema (LE) of the upper extremity.

      SECONDARY OBJECTIVES:

      I. Compare the medical outcomes for patients receiving LVB surgery with those receiving
      standard surgery without the intervention.

      OUTLINE: Patients are randomized to 1 of 2 groups.

      GROUP I: Patients receive indocyanine green intravenously (IV) and undergo lymphangiography,
      then undergo LVB at the time of ALND.

      GROUP II: Patients do not receive indocyanine green, undergo lymphangiography, nor undergo
      LVB at the time of ALND.

      After completion of study, patients are followed up at 2 weeks, and then at 6, 12, and 18
      months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 14, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Volumetric diagnosis of lymphedema</measure>
    <time_frame>18 months</time_frame>
    <description>If the limb volume change, meets the criteria for a diagnosis of lymphedema at any time (5 percent, change), then the patient receives a diagnosis of lymphedema.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of lymphedema</measure>
    <time_frame>18 months</time_frame>
    <description>Will compare the incidence of lymphedema after mastectomy and axillary lymph node dissection surgery between two surgical techniques.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Anatomic Stage III Breast Cancer AJCC v8</condition>
  <condition>Anatomic Stage IIIA Breast Cancer AJCC v8</condition>
  <condition>Anatomic Stage IIIB Breast Cancer AJCC v8</condition>
  <condition>Anatomic Stage IIIC Breast Cancer AJCC v8</condition>
  <condition>Inflammatory Breast Carcinoma</condition>
  <condition>Prognostic Stage III Breast Cancer AJCC v8</condition>
  <condition>Prognostic Stage IIIA Breast Cancer AJCC v8</condition>
  <condition>Prognostic Stage IIIB Breast Cancer AJCC v8</condition>
  <condition>Prognostic Stage IIIC Breast Cancer AJCC v8</condition>
  <arm_group>
    <arm_group_label>Group I (LVB)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive indocyanine green IV and undergo lymphangiography, then undergo LVB at the time of ALND.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II (no intervention)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients do not receive indocyanine green, undergo lymphangiography, nor undergo LVB at the time of ALND.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indocyanine Green</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group I (LVB)</arm_group_label>
    <other_name>ICG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Lymphangiography</intervention_name>
    <description>Undergo lymphangiography</description>
    <arm_group_label>Group I (LVB)</arm_group_label>
    <other_name>Lymphography</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Lymphovenous Bypass</intervention_name>
    <description>Undergo LVB</description>
    <arm_group_label>Group I (LVB)</arm_group_label>
    <other_name>Lymphovenous Anastomosis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients willing to participate.

          -  Patients able to complete informed consent.

          -  Patients with inflammatory breast cancer, and those with locally advanced
             non-inflammatory breast cancer that are undergoing ALND and are anticipated to receive
             radiation therapy.

        Exclusion Criteria:

          -  Patients taking anticoagulants within 7 days prior to surgery.

          -  Patients that are known to be pregnant at the time of surgery.

          -  Patients are available for follow-up less than 18 months.

          -  Patients with known iodine hypersensitivity.

          -  Patients with known hypersensitivity to indocyanine green (ICG).

          -  Patients with body mass index (BMI) greater than 40.0.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Schaverien</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mark Schaverien</last_name>
    <phone>713-794-1247</phone>
    <email>mvschaverien@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Schaverien</last_name>
      <phone>713-794-1247</phone>
    </contact>
    <investigator>
      <last_name>Mark Schaverien</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>May 6, 2019</study_first_submitted>
  <study_first_submitted_qc>May 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2019</study_first_posted>
  <last_update_submitted>March 13, 2020</last_update_submitted>
  <last_update_submitted_qc>March 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Inflammatory Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

